The ESCMID Study Group on Biofilms (ESGB) is at the forefront of biofilm research and collaboration. United by a shared vision, this group brings together specialists from around the globe and are dedicated to:
To update or not to update the ESCMID guidelines for the diagnosis and treatment of biofilm infections – That is the question! The opinion of the ESGB board.
Høiby N, Moser C, Oliver A, Williams C, Ramage G, Borghi E, Azeredo J, Dolores Macia M, ESGB board. Biofilm. 2023;6:100135.
A systematic review of the use of bacteriophages for in vitro biofilm control.
Meneses L, Brandão AC, Coenye T, Braga AC, Pires D, Azeredo J . Eur J Clin Microbiol Infect Dis. 2023;42(8):919-928.
Our current clinical understanding of Candida biofilms: where are we two decades on?
Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. APMIS. 2023;131(11):636-653.
Combining phages and antibiotic to enhance antibiofilm efficacy against an in vitro dual species wound biofilm.
Akturk E, Melo LDR, Oliveira H, Crabbé A, Coenye T, Azeredo J. Biofilm. 2023;6:100147.
Biofilm Corner 5: Cardiovascular Infections as a Biofilm Problem
05 December 2024, 15:00-16:00 CET
Biofilm Corner 4: Double-edge weapons: drugs with unexpected effects on biofilms development
23 May 2024
Biofilm Corner 2: extracellular vesicles in biofilms
Biofilm Corner 3: Biofilm control using bacteriophages
If you have questions or comments for our study group, we warmly invite you to contact us!
